---
title: "Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook"
date: "2025-02-13 04:54:26"
summary: "Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/12/Cambridge--Ma--Usa---June-29--2022-Bioge.jpeg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

[benzinga](https://www.benzinga.com/general/biotech/25/02/43673992/biogen-delivers-q4-beat-analyst-focuses-on-leqembi-expansion-2025-outlook)
